Auritec Pharmaceutics

1
Auritec Pharmaceutics

• Privately held
• Drug Delivery
• Platform technology
• Multiple applications
• Goal is to license
• 2nd company founded by TJS

2
CDS

• 1st company Control Delivery Systems
• CDS founded 1990
• First round financing 34.5 M 1999
• Morgan Stanley / Cap Research / T. Rowe Price
• Public- reverse acquisition pSivida Ltd (AUS)
• Trades NASDAQ (PSDV)

3
Auritec

• Founded 2002
• Delaware C
• Offices Santa Monica CA, Boston MA
• Labs Pasadena CA
• Multiple academic and industry collaborators

4
Collaborators

• Harvard
• Caltech
• Albert Einstein
• USC
• U Mass
• Emory
• UNC

• Gates Foundation
• CDC
• CONRAD
• USAID
• IPM
• Charles River
• NC State

5
Plexis Technology Platform

• Injectable subcutaneous suspension
• Polymer encapsulation
• Diffusion based release
• Small or large molecules
• IVIVC feasible

6
IV / IV release - nevirapine
7
IV / IV release - nevirapine
In vivo release
8
IV / IV - olanzapine
9
IV / IV - olanzapine
10
IV / IV cyclosporine
11
IV / IV cyclosporine
12
Comparison to ALKS

• Auritec
• Particle size 100u
• Drug loading gt 90
• Diffusion based
• First and pseudo-zero order possible
• IVIVC feasible

• Alkermes
• Particle size 100u
• Drug loading lt20
• Complex mechanism
• Multiphasic delivery
• No IVIVC

13
Existing SR injectables

• Risperdal Consta
• Leuprorelin
• Contraception
• Benzathine and procaine penicillin
• Zinc Insulins
• Corticosteroids

14
SR injectable indications

• Osteoarthritis
• Schizophrenia
• Parkinsons
• Diabetic retinopathy
• Menieres
• HIV transmission

• Alzheimers
• Depression
• Malaria
• TB
• Diabetes (GLPs)
• Influenza

15
Time to Phase I/II

• 2010 Parkinsons HIV Transmission
• Herpes Simplex
• Diabetic retinopathy
• Otoprotection
• Arthritis
• 2011 Malaria
• TB
• Incontinence
• Graft Rejection

16
Business Model

• Bootstrap
• pSivida, NIH, other granting agencies
• Fully funded through 2011
• License
• Sell firstborn not self
• Phase II clinical
• Non-profit for no profits

17
Deals with Big Pharma
18
Strategy
19
(No Transcript)